GLP-1 drugs

GLP-1 drugs like Ozempic and Wegovy, originally framed as obesity treatments for patients with medical need, are increasingly being marketed and used as lifestyle products aimed at customers seeking cosmetic or wellness benefits. Observers note this shift raises questions about how the drugs are prescribed, who accesses them, and how the industry frames their purpose as demand widens beyond clinical obesity care.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

New reporting highlights that young people taking GLP-1 receptor agonists, a class of drugs widely used for weight management and diabetes, are showing nutritional deficiencies. Clinicians are being advised to monitor nutrient intake in pediatric and adolescent patients on these medications, as appetite suppression may reduce overall consumption of essential vitamins and minerals during critical growth years.